Use of Bevacizumab in Advanced Ovarian Cancer: Consensus from an Expert Panel Oncologists
Tóm tắt
To discuss and reach a consensus on the use of bevacizumab in women with advanced ovarian cancer in Indian settings.
An advisory board meeting comprising Indian oncologists was convened to review key literature available on the role of bevacizumab in the management of advanced ovarian cancer. Key recommendations were devised via consensus by the expert panel based on the analysis of available scientific evidence and clinical experience. The expert panel recommends the use of bevacizumab in patients with advanced ovarian cancer in first-line settings, as well as in recurrent settings. This document summarizes key discussion points and recommendations provided by the advisory panel, which helps guide clinicians on the use of bevacizumab for managing advanced ovarian cancer in the Indian setting. It also acts as a pragmatic tool to assist clinicians in making appropriate treatment decisions with respect to advanced ovarian cancer.
Tài liệu tham khảo
Desai A, Xu J, Aysola K, et al. Epithelial ovarian cancer: an overview. World J Transl Med. 2014;3:1–8.
World Ovarian Cancer Coalition 2018. The World Ovarian Cancer Coalition Atlas. 2018. https://worldovariancancercoalition.org/wp-content/uploads/2018/10/THE-WORLD-OVARIAN-CANCER-COALITION-ATLAS-2018.pdf. Accessed 9 Feb 2019.
IACR. Globocan 2018 India Factsheet. http://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf. Accessed 9 Feb 2019.
Berek JS, Kehoe ST, Kumar L, et al. Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2018;143:59–78.
Santaballa A, Barretina P, Casado A, et al. SEOM clinical guideline in ovarian cancer. Clin Transl Oncol. 2016;18:1206–12.
Avastin SmPC. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf. Updated 28 Mar 2018. Accessed 9 Feb 2019.
Melosky B, Reardon DA, Nixon AB, et al. Bevacizumab biosimilars: scientific justification for extrapolation of indications. Future Oncol. 2018;14:2507–20.
US FDA. FDA approves bevacizumab in combination with chemotherapy for ovarian cancer https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610664.htm. Accessed 9 Feb 2019.
EMA. EPAR summary for the public. https://www.ema.europa.eu/documents/overview/avastin-epar-summary-public_en.pdf. Accessed 9 Feb 2019.
NCCN. NCCN clinical practice guidelines in oncology. Ovarian cancer. 2020. https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf. Accessed 30 Sept 2020.
Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30:672–705.
Guyatt GH, Oxman AD, Vist GE, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.
Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.
Burger RA, Enserro D, Tewari KS, et al. Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: a NRG oncology/Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2018;36:5517.
Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928–36.
Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039–45.
Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:779–91.
Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302–8.
Lee JY, Park JY, Park SY, et al. Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): a Korean Gynecologic Oncology Group study (KGOG 3041). Gynecol Oncol. 2019;152:61–7.
Trillsch F, Mahner S, Hilpert F, et al. Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. Ann Oncol. 2016;27:1733–9.
Rouzier R, Gouy S, Selle F, et al. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial. Eur J Cancer. 2017;70:133–42.
Garcia YGD, Juan A, Mendiola C, et al. Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC) (GEICO 1205/NOVA TRIAL). J Clin Oncol. 2017;35:5508.
Chopra R, Lopes G. Improving access to cancer treatments: the role of biosimilars. J Glob Oncol. 2017;3:596–610.
European Medicines Agency. Biosimilar medicines: overview. https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview. Accessed 19 Dec 2019.
Rugo HS, Rifkin RM, Declerck P, et al. Demystifying biosimilars: development, regulation and clinical use. Future Oncol. 2019;15:777–90.